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A B S T R A C T
To date 45 autosomal recessive disease-causing variants are reported in the FKBP10 gene. Those variant were
found to be associated with Osteogenesis Imperfecta (OI) for which the hallmark phenotype is bone fractuers or
Bruck Syndrome (BS) where bone fractures are accompanied with contractures. In addition, a specific homo-
zygous FKBP10 mutation (p.Tyr293del) has been described in Yup'ik Inuit population to cause Kuskokwim
syndrome (KS) in which contractures without fractures are observed. Here we present an extended Palestinian
family with 10 affected individuals harboring a novel homozygous splice site mutation, c.391+4A > T in
intron 2 of the FKBP10 gene, in which the three above mentioned syndromes segregate as a result of skipping of
exon 2 and absence of the FKBP65 protein. At the biochemical level, Hydroxylysyl pyridinoline (HP)/lysyl
pyridinoline (LP) values were inversely correlated with OI phenotypes, a trend we could confirm in our patients.
Our findings illustrate that single familial FKBP10 mutations can result in a phenotypic spectrum, ranging from
fractures without contractures, to fractures and contractures and even to only contractures. This broad intra-
familial clinical variability within one single family is a new finding in the field of bone fragility.
1. Introduction
Osteogenesis imperfecta (OI) is a heterogeneous heritable con-
nective tissue disorder, also known as “brittle bone disease”, that is
characterized by bone fragility, deformity and significant growth defi-
ciency. This skeletal dysplasia may manifest other features including
blue sclerae, hearing loss and dentinogenesis imperfecta. The under-
lying defects result in deficiency or structural abnormality of type I
collagen, the main protein of tendon, skin and bone. The most frequent
forms of OI are autosomal dominantly inherited and caused by muta-
tions in COL1A1 (OMIM 120150) or COL1A2 (OMIM 120160) encoding
type I collagen monomers. The spectrum of associated phenotypes vary
from prenatal death to a very low fracture frequency (Sillence et al.,
1979; Bonafe et al., 2015).
Since 2006 the molecular basis of several rare recessive forms of OI
was identified which involve abnormalities in procollagen post-
translational modification, collagen folding and crosslinking, bone
formation and mineralization (Sup. Table 1) (Forlino and Marini,
2016).
Defects in FKBP10 (OMIM 607063) which encodes FKBP65 protein,
cause autosomal recessive OI (type XI). This chaperone molecule
localizes in the endoplasmic reticulum and belongs to the peptidyl-
prolyl cis-trans isomerase (PPIase) family (Alanay et al., 2010; Ishikawa
et al., 2008). FKBP65 protein is believed to play an important role in the
hydroxylation of collagen telopeptide lysines, the essential process for
generating collagen cross links that provide fibril tensile strength and
stability. Also, FKBP65 deficiency was associated with reduced collagen
deposition into the extracellular matrix (Barnes et al., 2012).
FKBP65 deficiency was initially reported in patients with severe OI,
progressive scoliosis, and deforming long bone fractures in the absence
of blue sclerae, hearing loss, and dentinogenesis imperfecta (Alanay
et al., 2010). Subsequently, several reports associated FKBP65 with
Bruck syndrome 1 (BRKS1, OMIM 259450), an autosomal recessive
disorder characterized by congenital joint contractures, fragile bones,
severe limb deformities, and progressive scoliosis (Shaheen et al., 2010,
2011; Kelley et al., 2011). A second cause of Bruck syndrome (BRSK2,
OMIM 609220) results from defects in PLOD2 (OMIM 601865), en-
coding lysyl hydroxylase 2 (LH2), the enzyme responsible for collagen
telopeptide lysine hydroxylation (Puig-Hervas et al., 2012).
Further studies report on FKBP10 pathogenic variants presenting
with or without contractures within a same family, indicating that
BRSK1 and OI are allelic disorders with variable occurrence of
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contractures (Schwarze et al., 2013a; Caparros-Martin et al., 2013). A
specific homozygous FKBP10 deletion of a conserved tyrosine residue
(c.877_879del; p(Tyr293del); LOVD FKBP10_00017) was reported un-
iquely in a Yup'ik Inuit population to cause Kuskokwim syndrome (KS),
an arthrogryposis syndrome with less pronounced fracturing that ex-
pands the phenotypic range of FKBP65-related skeletal dysplasia. Hi-
therto, it is unknown if there is a specific genotype-phenotype corre-
lation for KS (Barnes et al., 2013; Petajan et al., 1969).
Here we present an extended consanguineous Palestinian family
with a homozygous FKBP10 mutation in which the three above men-
tioned syndromes, OI, BS1 and KS, are represented.
1.1. Patient data
Previously, we reported on eight patients of a consanguineous
Palestinian family harboring the novel homozygous splice site variant
c.391+4A > T in the FKBP10 gene (OI variant database (https://oi.
gene.le.ac.uk); LOVD DB ID FKBP10_00031) (Essawi et al., 2018;
Dalgleish, 1997, 1998). All eight patients were diagnosed with Bruck
syndrome based on recurrence of long bone fractures and congenital
contractures. We now re-evaluated the disease spectrum in this family
in detail and obtained thirteen additional blood samples (IV: 1–8 & V:
1,10,16,17 &19) for variant analysis. Informed consent from the par-
ticipant and/or the legal guardian was obtained, and the study was
approved by the ethics committee of the Ghent University Hospital and
was performed in compliance with the Declaration of Helsinki.
2. Methods
2.1. Cell culture and isolation of DNA and RNA
Genomic DNA was isolated and purified from whole EDTA-blood by
Qiagen DNeasy Kit using standard protocols (Qiagen, Frankfurt,
Germany). A skin biopsy was obtained from the proband (V:6). Cells
were cultured in Dulbecco's modified Eagle's medium (DMEM) sup-
plemented with 10% fetal bovine serum (FBS), 10 IU/ml penicillin, 100
μg/ml kanamycin, 25 μg/mL fungizone, and 1% non-essential amino
acid (NEAA) Solution 100X (all purchased from Invitrogen ™, Thermo
Fisher Scientific, Inc., Waltham, MA, USA), and incubated at 37 °C with
5% CO2. RNA was isolated with the RNeasy mini kit (Qiagen,
Frankfurt, Germany). Subsequently, cDNA was synthesized using the M-
MLV cDNA synthesis kit according to the manufacturer's instructions
(Qiagen, Frankfurt, Germany).
2.2. Sequencing and expression analysis
The splice site variant and exon skipping were confirmed by bidir-
ectional Sanger Sequencing using an ABI3730XL sequencer (Applied
Biosystems, Inc., Foster City, CA) at gDNA and cDNA level, respectively.
Nomenclature is based on the HGMD guidelines and refers to NCBI
reference sequence NM_021939.3 for FKBP10 and NP_068758.3 for
FKBP65. Gene expression was investigated by reverse-transcription
quantitative PCR (RT-qPCR) (primers and conditions available upon
request). Data was analyzed by qBase Plus (Biogazelle, Ghent, Belgium)
using the reference genes HPRT1, YWHAZ, and RPL13A for normal-
ization.
2.3. Western blotting and protein analysis
Patient and control fibroblasts' cell lysate were extracted using NP-
40 lysis buffer (Thermo Fisher Scientific, Merelbeke, Belgium), ac-
cording to the manufacturer's protocol. Western blotting was performed
using electrophoresis system with NuPage 4–12% Bis-Tris 1.5 mm x 10
wells mini gels and transferred to a Nitrocellulose membrane (Life
Technologies Europe, Merelbeke, Belgium). Precision Plus Protein All
Blue standard was used for monitoring electrophoretic separation and
molecular weight sizing (Bio-Rad Laboratories, Temse, Belgium). The
membrane was blocked with 3% ECL blocking agent (Fisher Scientific,
Brussels, Belgium). Afterwards, the membrane was incubated overnight
with 1:500 Anti-FKBP10 (HPA051171) primary antibody (Sigma-
Aldrich, Overijse, Belgium). Subsequently, the membrane was washed
and incubated with 1:2500 anti-rabbit secondary antibody (Abcam,
Cambridge, UK). α-Tubulin (1:1000) was used as a protein loading
control (Sigma-Aldrich, Overijse, Belgium).
2.4. HP and LP cross-linking analysis
Urine samples obtained from five patients (V:5, V:9, V:12, V:13, and
V:19) and three non-affected family members (IV:8, V:15, V:17) were
hydrolyzed in 6N HCl, dried and the material re-dissolved in 10% acetic
acid. The soluble material was loaded on a Bio-Gel P-2 column
(1.5 cm × 30 cm, (Bio-Rad Laboratories, CA, United States) and then
eluted with 10% acetic acid. The fractions that contained pyridinolines
were pooled for quantitative analysis by C18 reverse-phase HPLC (Eyre,
1987).
3. Results
3.1. Molecular analysis and phenotypic description
The pedigree of the family is presented in Fig. 1. Molecular analysis
revealed that all patients’ parents (IV: 1–8) and two further family
members (V:10 &17) were heterozygous carriers of the splice site var-
iant c.391+4A > T in the FKBP10 gene (OI variant database (https://
oi.gene.le.ac.uk); LOVD DB ID FKBP10_00031). Two other family
members did not carry the variant. None of these individuals presented
with a skeletal phenotype. Patient V:19, a six years old boy, was di-
agnosed with arthrogryposis and was found to harbor the same
homozygous splice site variant. He only showed congenital contractures
without any fractures. In addition, one OI patient (V: 11), presenting
with the most severe phenotype, according to the family, died at the age
23 years due to the complications of progressive kyphoscoliosis causing
respiratory deficiency and pain (no DNA available). Another affected
family member (V: 8) died at the age of 32 years suffering from similar
symptoms with shortness of breath and chest pain. Overall, patient ages
ranged from 6 to 46 years. The main clinical features reported are blue
sclerae (10/10) (becoming less obvious with increasing age), pro-
gressive kyphoscoliosis (7/10), club feet (6/10), dentinogenesis im-
perfecta (3/10) and inguinal hernia (2/10). None of the patients had
hearing loss (Table 1). All ten patients were classified according to
severity and main presenting features, as indicated in Tables 2 and 3.
The first group includes patients with severe OI (> 100 fractures) and
no or very mild contractures, progressive kyphoscoliosis and lower
Fig. 1. Pedigrees of the family that participated in this study. Asterisk (*)
indicates family members from whom DNA was obtained. Segregation analysis
revealed that ten family members designated with half shaded shapes were
heterozygous carriers and two were non-carriers. Whereas nine affected in-
dividuals of whom DNA was available harbor the homozygous splice site var-
iant. Group 1 patients denoted by black shapes; Group 2 patients denoted by
stripped shapes; Group 3 patients denoted by black shapes labeled with an
internal white circle; and finally Group 4 patient denoted by a black square
labeled with an internal white rhomboid. See Table 2 for the phenotype de-
scription of the different groups.
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limbs hypotonia. The second group presented with moderate OI (> 50
fractures) with mild to moderate arthrogryposis, no or mild ky-
phoscoliosis, hypotonia of the lower limbs, inguinal hernias and club
feet. The third group showed mild OI (< 20 fractures) with moderate to
severe arthrogryposis, mild to moderate kyphoscoliosis, upper and
lower limb hypotonia, and club feet. The fourth group contains patients
with severe arthrogryposis without any fractures, and hypotonia of the
upper and lower limbs. An inverse relationship between the severity of
the OI and the contractures is observed (Fig. 4).
3.2. Functional analysis
We investigated the effect of the c.391+4A > T variant at the
cDNA level, revealing a 146 bp out-of-frame deletion of exon 2, re-
sulting in a deletion of 48 amino acids and a premature stop codon. RT-
qPCR of FKBP10 expression showed a 10-fold down regulation in the
proband V:6 compared to an age and sex matched control. Loss of ex-
pression was confirmed by the absence of FKBP65 on Western blotting
in the proband's fibroblasts. All results are illustrated in Fig. 2.
3.3. HP and LP cross-linking analysis
Hydroxylysyl pyridinoline (HP) and lysyl pyridinoline (LP) cross-
linking was measured in urine samples of five patients and three non-
affected family member. The HP to LP ratios obtained are shown in Sup.
Table 2. Control samples (IV:8, V:15 and V:17) show ratios within the
normal range. Patients HP/LP are within normal range for the two older
patients V:5 and V:9, but higher than normal for the younger patients
V:12, V:13 and V:19. The latter observation is in concordance with
previous findings in patients with FKBP10 mutations and appears to
account for HP derived from calcified cartilage type II collagen and not
bone type I collagen (Schwarze et al., 2013a). Hence, the increased
ratios in younger patients may relate to active growth where type II
collagen is continuously broken down from the growth plate.
4. Discussion
We report on an extended Palestinian consanguineous family with
10 affected family members presenting a phenotypic spectrum ranging
from severe OI to isolated arthrogryposis. To date 45 disease-causing
variants are reported in the FKBP10 gene (Fig. 3 and Sup. Table 3),
originating from different populations, making FKBP10 the second most
prevalent recessive OI gene after P3H1 (OMIM 610915) according to
the OI variant database (Dalgleish, 1997, 1998). Fig. 3 illustrates that
FKBP10 pathogenic variants are distributed over the entire gene. Most
pathogenic variants are frameshift variants (21/45), followed by non-
sense (10/45) missense (5/45), splice site (5/5) and in-frame (3/45)
variants. There are no clear genotype-phenotype correlations with any
of three disease presentations (Table 3). Four variants (4/45) cause
both BS and OI, and one (1/45) in-frame deletion variant cause KS
Table 1
Clinical data of the patients harboring the homozygous splice site variant c.391 + 4A > T. Group 1 includes patients with severe OI and no or very mild
contractures; Group 2 includes patients with moderate OI and mild to moderate arthrogryposis; Group 3 includes patients with mild OI and moderate to severe
arthrogryposis; Group 4 includes the patient with severe arthrogryposis and no fractures. See Fig. 4.
†* Died at the age of 32 and 23 respectively.
‡Patient ID corresponds to the identifiers found in Fig. 1: Family Pedigree.
§ +, ++, +++ or ++++ indicates the severity.












V:3 F 12 >30 + + + + ++ – – + 2
V:5 F 46 >50 + + + – ++ + + + 2
V:6 M 44 >50 + + + – ++ + + + 2
V:8 M 32* >100 + – + + + – – + 1
V:9 F 34 >100 + – + + + – – + 1
V:11 F 23* > 100 + – + + – – – + 1
V:12 F 18 20 + + + + +++ – – + 3
V:13 M 17 17 + + + + +++ – + + 3
V:14 M 9 9 + + + + +++ – – + 3
V:19 M 6 0 + – – – ++++ – – – 4
Table 2
Phenotype description of the patients harboring the homozygous splice site variant c.391+4A > T. Comparison between the different patient groups according to
the phenotypes presented.
Group1
V: 8, 9 & 11
Group 2
V: 3, 5 & 6
Group 3
V: 12, 13 & 14
Group 4
V: 19
Phenotype Severe OI/No or mild Ar Moderate OI/Mild-Moderate Ar Mild OI/Moderate–Severe Ar Arthyrogryposis (Ar)
Fractures >100 >50 <25 No
Contractures No or Hardly detectable Mild Moderate Severe
Upper limbs hypotonia No No Yes Yes
Lower limbs hypotonia Yes Yes Yes Yes
Kyphoscoliosis Severe No or mild Mild - Moderate No
Dentinogenesis Imperfecta No Yes Yes No
Blue sclaere Diminishes with age Diminishes with age Diminishes with age Diminishes with age
Inguinal Hernia No Yes No No
Club foot No Yes Yes No
Table 3
Variant effect versus severity of the phenotype. A chi-square test to verify if
frameshift variants in FKBP10 are more likely to cause OI rather than BS is not
significant (p-value of 0.310494; p < 0.5).
Effect Total # OI BS KS OI + BS OI + BS + KS
Frameshift 21/45 6 12 3
Nonsense 10/45 6 4
Missense 5/45 2 2 1
Splice-site 5/45 4 1
In-Frame 3/45 1 1 1
Other 1/45 1
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(Table 3 & Sup. Fig. 1). The most frequent FKBP10 variant c.831dupC p.
(Gly278Argfs∗95), was reported both for OI and BS, but not for KS in
several population groups worldwide (Alanay et al., 2010; Shaheen
et al., 2011; Kelley et al., 2011; Schwarze et al., 2013a; Caparros-Martin
et al., 2013, 2017; Vorster et al., 2017; Mrosk et al., 2018; Xu et al.,
2017; Umair et al., 2016; Alabdullatif et al., 2017).
Several reports describe inter- and intra-familial variability en-
compassing both BS and OI related phenotypes (Alanay et al., 2010;
Shaheen et al., 2010, 2011; Kelley et al., 2011; Schwarze et al., 2013a;
Caparros-Martin et al., 2017). However, in all OI and BS families re-
ported with FKBP10 mutations, there are no patients without a fracture
and only contractures, except for the Kuskokwim cohort. This suggests
that the KS phenotype is peculiar to the specific FKBP10 variant that
result in an in-frame deletion of the conserved p.Tyr293 in FKBP65
(Barnes et al., 2013). It was suggested that OI and BS phenotypes might
result from absent FKBP65 protein and undetectable hydroxylation of
type I collagen telopeptide lysines, whereas the in-frame deletion mu-
tation causing KS destabilized the FKBP65 protein. A residual amount
that accounted for an observed 2–10% hydroxylation of the telopeptide
lysines was observed (Barnes et al., 2013). In our study, proband V:6
(diagnosed with BS) had a 10-fold reduction in FKBP10 gene expression
compared to controls, but no residual FKBP65 protein (Fig. 2).
FKBP10 deficiency results in reduced hydroxylation of telopeptide
lysine of type I collagen in bone or cultured fibroblast samples (Barnes
et al., 2012, 2013; Schwarze et al., 2013a; Duran et al., 2017; Bank
Fig. 2. Functional Data. A: Schematic representa-
tion of the aberrant splicing process in FKBP10. The
Boxes denote the exons, and the solid lines indicate
the introns. B: c.DNA sequencing of the proband V:6
harboring the homozygous splice site variant
c.391+4A > T revealed skipping of exon 2 of the
FKBP10 gene, predicted to result in an out-of-frame
deletion of 48 amino acids (146 bp). C: FKBP10 gene
expression indicating 10 fold down regulation in the
proband V:6 sample compared to a control sample.
D: Western blotting assay revealed the absence of
FKBP65 in the probands fibroblasts; Lane 1 indicates
all blue ladder, lane 2 indicates an immortalized
BJ5ta fibroblast cell line derived by transfecting the
BJ foreskin fibroblast cell line with the pGRN145
hTERT-expressing plasmid and obtained from a
neonatal male, lane 3 indicates an age and sex mat-
ched control fibroblasts and lane 4 indicates the
proband V:6 fibroblasts. (For interpretation of the
references to colour in this figure legend, the reader
is referred to the Web version of this article.)
Fig. 3. FKBP10 variants. A-Pathogenic variants as-
sociated with the BS are indicated with green arrows
and shown in the upper side of the figure, pathogenic
variants associated with OI are indicated in red ar-
rows and shown in the lower part. Black arrows in-
dicates pathogenic variants causing both BS and OI.
The orange arrow indicates the pathogenic variant
identified in this study causing BS, OI and KS and
finally the pink arrow indicates the in frame deletion
causing KS. Transcript sequence NM_021939.3 of the
FKBP10 gene consists of 10 coding exons. Most of the
OI causing variants were found in exon 5 and 6. B–
FKBP65 protein NP_068758.3 consists of six do-
mains: (i) PPIase FKBP-type 1 (residues 62–150), (ii)
PPIase FKBP-type 2 (residues 174–262), (iii) PPIase
FKBP-type 3 (residues 286–374), (iv) PPIase FKBP-
type 4 (residues 399–486), (v) EF-hand 1 (residues
497–532) and (vi) EF-hand 2 (residues 542–577).
Detailed information about all disease causing var-
iants in the FKBP10 gene are available in Sup.
Table 3. * The genomic deletion variant
g.39974881_39980318del (hg19) is not indicated on
the graph. . (For interpretation of the references to
colour in this figure legend, the reader is referred to
the Web version of this article.)
Fig. 4. Phenotypic heterogeneity in FKBP10 family. Schematic diagram of
the phenotype of FKBP10 variants illustrating the inverse relationship between
the severity of the OI and the contractures.
This diagram was derived and adapted from a publication of Barnes et al., 2013).
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et al., 1999). Hydroxylated telopeptide lysine varied from less than 1%
(controls 60%) in patients’ fibroblasts with null mutations and mod-
erate-severe OI (Barnes et al., 2012) to 4–6% hydroxylation (controls
75%) in bone samples of patients with a missense mutation and BS
(Bank et al., 1999; Schwarze et al., 2013b). Furthermore, Schwarze
et al. examined the hydroxylation of telopeptide lysine in a bone sample
of a BS patient with a null mutation revealing about 10% hydroxylation
of telopeptide lysine in comparison to a control. In KS patients due to
the p.Tyr293del variant telopeptide lysyl hydroxylation varied between
2 and 10% (controls 60%) (Barnes et al., 2013). Unfortunately, because
of the different tissues (bone vs fibroblasts) and different effect of the
mutations (null vs missense) analyzed, no conclusive results can be
obtained concerning the relation between the amount of telopeptide
lysine hydroxylation and the severity of the phenotype. Seemingly
contradictory, HP/LP crosslinking is higher in patient versus control
urine samples. This can be explained by a significant contribution to
urine HP by growth plate cartilage type II collagen breakdown for the
patient samples. We know that telopeptide hydroxylation of type II
collagen is unaffected by FKBP65 deficiency (Schwarze et al., 2013b).
Higher urine HP/LP values were inversely correlated with OI pheno-
types, a trend we could confirm in our patients (Sup. Table 2).
Our report highlights the wide clinical spectrum in our family in-
dicating that the three FKBP10-related disorders, OI, BS and KS, can be
caused by a same mutation.
Besides the inverse relationship between the severity of OI and the
contractures (Fig. 4), other manifestations including inguinal hernia,
club feet and dentinogenesis imperfecta did not seem to correlate with
the primary clinical diagnosis of either OI (Group 1 patients (V: 8, 9 &
11)) or arthrogryposis (Group 4 (V: 19) patient) (Table 2).
In conclusion, our data confirm the wide clinical spectrum and
intra-familial variability in FKBP10 related disease, and suggests that it
could contribute to the mutational spectrum of isolated arthrogryposes.
CRediT authorship contribution statement
Osama H. Essawi: Investigation, Validation, Resources, Writing -
original draft, Visualization. Piyanoot Tapaneeyaphan: Investigation,
Validation. Sofie Symoens: Writing - review & editing. Charlotte
Gistelinck C: Investigation, Validation. Fransiska Malfait: Writing -
review & editing. David R. Eyre: Writing - review & editing,
Supervision. Tamer Essawi: Supervision. Bert Callewaert: Writing -
review & editing. Paul J. Coucke: Supervision, Writing - review &
editing, Visualization, Funding acquisition.
Acknowledgements
We thank all the patients and their families who supported our re-
search efforts. We are grateful to Ahmad Thwaeb and Omar Mohammad
for blood and urine sampling.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ejmg.2020.103980.
Funding sources
F. M. and B. C. are fellows of the Fund for Scientific Research
(FWO). O. E. has a BOF Research Fellowship from the Ghent University.
Contract grants include FWO grant number G.0171.05 and Methusalem
grant number 08/01M01108 to A. D. P.
References
Alabdullatif, M.A., et al., 2017. Chromosomal microarray in a highly consanguineous
population: diagnostic yield, utility of regions of homozygosity, and novel mutations.
Clin. Genet. 91 (4), 616–622.
Alanay, Y., et al., 2010. Mutations in the gene encoding the RER protein FKBP65 cause
autosomal-recessive osteogenesis imperfecta. Am. J. Hum. Genet. 86 (4), 551–559.
Bank, R.A., et al., 1999. Defective collagen crosslinking in bone, but not in ligament or
cartilage, in Bruck syndrome: indications for a bone-specific telopeptide lysyl hy-
droxylase on chromosome 17. Proc. Natl. Acad. Sci. U.S.A. 96 (3), 1054–1058.
Barnes, A.M., et al., 2012. Absence of FKBP10 in recessive type XI osteogenesis imperfecta
leads to diminished collagen cross-linking and reduced collagen deposition in ex-
tracellular matrix. Hum. Mutat. 33 (11), 1589–1598.
Barnes, A.M., et al., 2013. Kuskokwim syndrome, a recessive congenital contracture
disorder, extends the phenotype of FKBP10 mutations. Hum. Mutat. 34 (9),
1279–1288.
Bonafe, L., et al., 2015. Nosology and classification of genetic skeletal disorders: 2015
revision. Am. J. Med. Genet. 167A (12), 2869–2892.
Caparros-Martin, J.A., et al., 2013. Clinical and molecular analysis in families with au-
tosomal recessive osteogenesis imperfecta identifies mutations in five genes and
suggests genotype-phenotype correlations. Am. J. Med. Genet. 161A (6), 1354–1369.
Caparros-Martin, J.A., et al., 2017. Molecular spectrum and differential diagnosis in pa-
tients referred with sporadic or autosomal recessive osteogenesis imperfecta. Mol.
Genet. Genom. Med. 5 (1), 28–39.
Dalgleish, R., 1997. The human type I collagen mutation database. Nucleic Acids Res. 25
(1), 181–187.
Dalgleish, R., 1998. The human collagen mutation database 1998. Nucleic Acids Res. 26
(1), 253–255.
Duran, I., et al., 2017. A chaperone complex formed by HSP47, FKBP65, and BiP mod-
ulates telopeptide lysyl hydroxylation of type I procollagen. J. Bone Miner. Res. : Off.
J. Am. Soc. Bone Min. Res. 32 (6), 1309–1319.
Essawi, O., et al., 2018. Genetic analysis of osteogenesis imperfecta in the Palestinian
population: molecular screening of 49 affected families. Mol. Genet. Genom. Med. 6
(1), 15–26.
Eyre, D., 1987. Collagen cross-linking amino acids. Methods Enzymol. 144, 115–139.
Forlino, A., Marini, J.C., 2016. Osteogenesis imperfecta. Lancet 387 (10028), 1657–1671.
Ishikawa, Y., et al., 2008. The rough endoplasmic reticulum-resident FK506-binding
protein FKBP65 is a molecular chaperone that interacts with collagens. J. Biol. Chem.
283 (46), 31584–31590.
Kelley, B.P., et al., 2011. Mutations in FKBP10 cause recessive osteogenesis imperfecta
and Bruck syndrome. J. Bone Miner. Res. : Off. J. Am. Soc. Bone Min. Res. 26 (3),
666–672.
Mrosk, J., et al., 2018. Diagnostic strategies and genotype-phenotype correlation in a
large Indian cohort of osteogenesis imperfecta. Bone 110, 368–377.
Petajan, J.H., et al., 1969. Arthrogryposis syndrome (Kuskokwim disease) in the eskimo.
J. Am. Med. Assoc. 209 (10), 1481–1486.
Puig-Hervas, M.T., et al., 2012. Mutations in PLOD2 cause autosomal-recessive con-
nective tissue disorders within the Bruck syndrome–osteogenesis imperfecta pheno-
typic spectrum. Hum. Mutat. 33 (10), 1444–1449.
Schwarze, U., et al., 2013a. Mutations in FKBP10, which result in Bruck syndrome and
recessive forms of osteogenesis imperfecta, inhibit the hydroxylation of telopeptide
lysines in bone collagen. Hum. Mol. Genet. 22 (1), 1–17.
Schwarze, U., et al., 2013b. Mutations in FKBP10, which result in Bruck syndrome and
recessive forms of osteogenesis imperfecta, inhibit the hydroxylation of telopeptide
lysines in bone collagen. Hum. Mol. Genet. 22 (1), 1–17.
Shaheen, R., et al., 2010. FKBP10 and Bruck syndrome: phenotypic heterogeneity or call
for reclassification? Am. J. Hum. Genet. 87 (2), 306–307 author reply 308.
Shaheen, R., et al., 2011. Mutations in FKBP10 cause both Bruck syndrome and isolated
osteogenesis imperfecta in humans. Am. J. Med. Genet. 155A (6), 1448–1452.
Sillence, D.O., Senn, A., Danks, D.M., 1979. Genetic heterogeneity in osteogenesis im-
perfecta. J. Med. Genet. 16 (2), 101–116.
Umair, M., et al., 2016. Homozygous sequence variants in the FKBP10 gene underlie
osteogenesis imperfecta in consanguineous families. J. Hum. Genet. 61 (3), 207–213.
Vorster, A., et al., 2017. Osteogenesis imperfecta type 3 in South Africa: causative mu-
tations in FKBP10. South African medical journal = Suid-Afrikaanse tydskrif vir
geneeskunde 107 (5), 457–462.
Xu, X.J., et al., 2017. Novel mutations in FKBP10 in Chinese patients with osteogenesis
imperfecta and their treatment with zoledronic acid. J. Hum. Genet. 62 (2), 205–211.
O.H. Essawi, et al. European Journal of Medical Genetics 63 (2020) 103980
5
